Krystal Biotech, Inc. Forecast, price target & analysts
Krystal Biotech, Inc. Target price 2025 - Analyst rating & recommendation
Krystal Biotech, Inc. Classifications & Recommendation:
Krystal Biotech, Inc. Price Target
| Target Price | $211.20 |
| Price | $139.43 |
| Potential |
51.47%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Krystal Biotech, Inc. 2026 .
The average Krystal Biotech, Inc. target price is $211.20.
This is
51.47%
register free of charge
$245.00
75.72%
register free of charge
$189.00
35.55%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Krystal Biotech, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Krystal Biotech, Inc. stock has an average upside potential 2026 of
51.47%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 290.52 | 417.14 |
| 473.02% | 43.58% | |
| EBITDA Margin | 37.84% | 49.40% |
| 120.80% | 30.54% | |
| Net Margin | 29.84% | 41.66% |
| 34.24% | 39.60% |
10 Analysts have issued a sales forecast Krystal Biotech, Inc. 2025 . The average Krystal Biotech, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Krystal Biotech, Inc. EBITDA forecast 2025. The average Krystal Biotech, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Krystal Biotech, Inc. Analysts have issued a net profit forecast 2025. The average Krystal Biotech, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.00 | 6.01 |
| 669.23% | 100.33% | |
| P/E | 23.19 | |
| EV/Sales | 8.20 |
4 Analysts have issued a Krystal Biotech, Inc. forecast for earnings per share. The average Krystal Biotech, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Krystal Biotech, Inc....
Current Krystal Biotech, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 29 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
